{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:15:44Z","timestamp":1790817344871,"version":"4.1.0"},"reference-count":44,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in achieving a complete remission in a range of B-cell malignancies, most notably B-acute lymphoblastic leukaemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). However, there are limitations, including inability to manufacture CAR-T cells from the patient\u2019s own T cells, disease progression and death prior to return of engineered cells. T cell dysfunction is known to occur in cancer patients, and several groups have recently described differences in CAR-T cells generated from chronic lymphocytic leukaemia (CLL) patients compared with those from a healthy donor. This is thought to contribute to the low response rate in this disease group. Healthy donor, gene-edited CAR-T cells which do not require human leucocyte antigen (HLA) matching have the potential to provide an \u2018off the shelf\u2019 product, overcoming the manufacturing difficulties of producing CAR-T cells for each individual patient. They may also provide a more functional, potent product for malignancies such as CLL, where T cell dysfunction is common and frequently cannot be fully reversed during the manufacturing process. Here we review the potential benefits and obstacles for healthy donor, allogeneic CAR-T cells.<\/jats:p>","DOI":"10.3390\/cells7100155","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T11:30:02Z","timestamp":1538479802000},"page":"155","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":163,"title":["Allogeneic CAR-T Cells: More than Ease of Access?"],"prefix":"10.3390","volume":"7","author":[{"given":"Charlotte","family":"Graham","sequence":"first","affiliation":[{"name":"Department of Haematological Medicine, King\u2019s College London, London SE5 9NU, UK"},{"name":"Department of Haematology, King\u2019s College Hospital NHS Foundation Trust, London SE5 9RS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Jozwik","sequence":"additional","affiliation":[{"name":"Department of Haematological Medicine, King\u2019s College London, London SE5 9NU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9795-1280","authenticated-orcid":false,"given":"Andrea","family":"Pepper","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, University of Sussex, Falmer BN1 9PX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Benjamin","sequence":"additional","affiliation":[{"name":"Department of Haematological Medicine, King\u2019s College London, London SE5 9NU, UK"},{"name":"Department of Haematology, King\u2019s College Hospital NHS Foundation Trust, London SE5 9RS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,10,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"key":"ref_7","unstructured":"Harper, M. (2017, August 20). Novartis CEO\u2019s Dilemma: Is $475,000 Too Much for a Leukaemia Breakthrough? Or Is It No Enough? 2017. Forbes Web site. Available online: https:\/\/www.forbes.com\/sites\/matthewherper\/2017\/08\/30\/novartis-ceos-dilemma-is-475000-too-much-for-a-leukemia-breakthrough-or-is-it-not-enough\/-367b613e556e."},{"key":"ref_8","unstructured":"(2018, July 20). Kite\u2019s Yescarta (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma after Two or More Lines of Systemic Therapy. Available online: https:\/\/www.gilead.com\/news\/press-releases\/2017\/10\/kites-yescarta-axicabtagene-ciloleucel-becomes-first-car-t-therapy-approved-by-the-fda-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-large-bcell-lymphoma-after-two-or-more-lines-of-systemic-therapy."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global Manufacturing of CAR T Cell Therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol. Ther. Meth. Clin. Dev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1182\/blood.V128.22.281.281","article-title":"Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR","volume":"128","author":"Lacey","year":"2016","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.V74.2.786.786","article-title":"T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease","volume":"74","author":"Totterman","year":"1989","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fimmu.2017.01956","article-title":"Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients","volume":"8","author":"Hoffmann","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/CJI.0000000000000193","article-title":"CD19 Chimeric Antigen Receptor T Cells from Patients with Chronic Lymphocytic Leukaemia Display an Elevated IFN-g Production profile","volume":"41","author":"Magalhaes","year":"2018","journal-title":"J. Immunother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-3-642-56352-2_8","article-title":"The role of immunosuppression in lymphoma","volume":"159","author":"Trofe","year":"2002","journal-title":"Recent Results Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/QAD.0000000000000071","article-title":"Malignancies in HIV\/AIDS: From epidemiology to therapeutic challenges","volume":"28","author":"Rubinstein","year":"2014","journal-title":"AIDS."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2015-08-662783","article-title":"T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells","volume":"128","author":"Azzaoui","year":"2016","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.clml.2016.08.003","article-title":"The T Cell in Myeloma","volume":"16","author":"Joshua","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.beha.2008.02.007","article-title":"Graft-versus-host disease after donor leukocyte infusions: Presentation and management","volume":"21","author":"Frey","year":"2008","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nm.4258","article-title":"Donor CD19 CART cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity","volume":"23","author":"Ghosh","year":"2017","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2017-08-752121","article-title":"Posttransplant chimeric antigen receptor therapy","volume":"131","author":"Smith","year":"2018","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bmt.2016.17","article-title":"Virus-specific T-cell banks for \u2018off the shelf\u2019 adoptive therapy of refractory infections","volume":"51","author":"Prockop","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40259-017-0247-0","article-title":"Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf","volume":"31","author":"Ruella","year":"2017","journal-title":"BioDrugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","article-title":"Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells","volume":"25","author":"MacLeod","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ymthe.2018.02.025","article-title":"Long Terminal Repeat CRISPR-CAR-Coupled \u201cUniversal\u201d T Cells Mediate Potent Anti-leukemic Effects","volume":"26","author":"Georgiadis","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Gilham, D.E., Michaux, A., Breman, E., Mauen, S., Bols\u00e9e, J., Huberty, F., Marijsse, J., Violle, B., Jacques-Hespel, C., and Marchand, C. (2018, January 5). TCR inhibitory molecule as a promising allogeneic NKG2D CAR-t cell approach. Proceedings of the 2018 ASCO Annual Meeting, Chicago, IL, USA.","DOI":"10.1200\/JCO.2018.36.15_suppl.e15042"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41419-018-0278-6","article-title":"CAR-T cells: The long and winding road to solid tumors","volume":"9","author":"Zizzari","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex Genome-Edited T-cell Manufacturing Platform for \u201cOff-the-Shelf\u201d Adoptive T-cell Immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/mt.2015.104","article-title":"A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy","volume":"23","author":"Valton","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.retram.2018.04.003","article-title":"CRISPR\/Cas9 genome editing: Fueling the revolution in cancer immunotherapy","volume":"66","author":"Liu","year":"2018","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.omtm.2017.01.005","article-title":"Genome-wide Specificity of Highly Efficient TALENs and CRISPR\/Cas9 for T Cell Receptor Modification","volume":"4","author":"Knipping","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/mt.2015.197","article-title":"Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR\/Cas9, and megaTAL Nucleases","volume":"24","author":"Osborn","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat. Biotechnol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/7\/10\/155\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:23:38Z","timestamp":1760196218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/7\/10\/155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10]]}},"alternative-id":["cells7100155"],"URL":"https:\/\/doi.org\/10.3390\/cells7100155","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}